DIBIZIDE M TAB

About

DIBIZIDE M TAB combines Gliclazide, a second-generation sulfonylurea, and Metformin, a biguanide, to provide comprehensive glycemic control for type 2 diabetes mellitus. Gliclazide stimulates insulin secretion from the pancreatic beta cells, primarily by closing ATP-sensitive potassium channels, leading to depolarization and calcium influx. Metformin acts by reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This dual action addresses both insulin secretion defects and insulin resistance, which are key pathophysiological features of type 2 diabetes. The combination is particularly effective for patients whose blood glucose levels are not adequately controlled by either monotherapy alone, offering improved HbA1c reduction and a favorable impact on cardiovascular risk factors.

Uses

• Management of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• When diet and exercise are insufficient.
• As an add-on to other antidiabetic agents.

Directions For Use

Take orally with meals, usually once or twice daily, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Potent blood glucose lowering.
• Addresses insulin resistance and secretion.
• Reduces HbA1c levels significantly.
• May aid in weight stabilization.
• Cardiovascular benefits (Metformin).
• Cost-effective treatment option.

Side Effects

• Hypoglycemia
• Nausea
• Diarrhea
• Abdominal pain
• Metallic taste
• Headache
• Dizziness
• Skin rash
• Lactic acidosis (rare, with Metformin)
• Vitamin B12 deficiency (long-term Metformin)
• Weight gain (Gliclazide)
• Indigestion

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of hypoglycemia and lactic acidosis (Metformin).
• Pregnancy - Not recommended during pregnancy. Insulin is generally preferred for glycemic control in pregnant women.
• Breastfeeding - Avoid during breastfeeding as components may pass into breast milk. Consult a doctor.
• Liver - Contraindicated in severe hepatic impairment due to increased risk of lactic acidosis and hypoglycemia.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of lactic acidosis. Dose adjustment needed for moderate impairment.
• Lung - Use with caution in severe acute or chronic lung disease due to potential for hypoxia, increasing lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.